Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
- Status
- COMPLETED
- Phase
- PHASE1
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Doxycycline, Temozolomide and Ipilimumab in Melanoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma
- Status
- TERMINATED
- Phase
- PHASE1
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
- Status
- COMPLETED
- Phase
- PHASE3
Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2